Intellia Therapeutics, Inc. vs UnitedHealth Group Incorporated — Stock Comparison
Q·Score Breakdown
6.2
Neutral
Overall
6.3
Neutral
Quality
Health
Growth
Valuation
Sentiment
NTLA
Clean balance sheet with low leverage (0.1× debt-to-equity).
⚠ low return on equity (-53%).
UNH
82% of 28 covering analysts have a positive rating.
⚠ limited growth momentum.
Analyst Consensus
BUY
Target $26.71 (+101.5%)
21 analysts
BUY
Target $387.27 (+5.0%)
26 analysts
Fundamentals
NTLA
UNH
—
Trailing P/E
27.9×
-4.6×
Forward P/E
17.8×
0.0%
Profit Margin
2.7%
0.0%
Gross Margin
18.8%
-53.5%
ROE
12.2%
78.8%
Revenue Growth
2.0%
—
Earnings Growth
0.7%
1.99
Beta
0.41
—
Price / Book
—
$1.6B
Market Cap
$334.9B
$7 – $28
52-Week Range
$235 – $410
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →